Content by Keyword: Prescription Drugs

Report page
Main Report

Models for Medication-Assisted Treatment for Opioid Use Disorder, Retention, and Continuity of Care. Main Report

TABLE OF CONTENTS ACKNOWLEDGMENTS ACRONYMS EXECUTIVE SUMMARY STUDY OBJECTIVES BACKGROUND Retention and Continuity of Care Defined Influences on Retention METHODS Literature Review Key Informant Interviews Case Studies RESEARCH FINDINGS
Report page
APPENDIX 4: Site Visit Reports

Models for Medication-Assisted Treatment for Opioid Use Disorder, Retention, and Continuity of Care. APPENDIX 4: Site Visit Reports

APPENDIX 4. SITE VISIT REPORTS IBM Watson Health July 2020 DISCLAIMER: The opinions and views expressed in this report are those of the authors. They do not reflect the views of the Department of Health and Human Services, the contractor or any other funding organization. This report was completed and submitted on September 7, 2019.   T
Report page
APPENDIX 3</A>: Site Interview Protocol

Models for Medication-Assisted Treatment for Opioid Use Disorder, Retention, and Continuity of Care. APPENDIX 3: Site Interview Protocol

APPENDIX 3. SITE INTERVIEW PROTOCOL IBM Watson Health July 2020 DISCLAIMER: The opinions and views expressed in this report are those of the authors. They do not reflect the views of the Department of Health and Human Services, the contractor or any other funding organization. This report was completed and submitted on March 29, 2019.  
Report page
APPENDIX 2: Case Studies Site Selection Criteria

Models for Medication-Assisted Treatment for Opioid Use Disorder, Retention, and Continuity of Care. APPENDIX 2: Case Studies Site Selection Criteria

APPENDIX 2. CASE STUDIES SITE SELECTION CRITERIA IBM Watson Health July 2020 DISCLAIMER: The opinions and views expressed in this report are those of the authors. They do not reflect the views of the Department of Health and Human Services, the contractor or any other funding organization. This report was completed and submitted on January 7
Report page
APPENDIX 1: Literature Review

Models for Medication-Assisted Treatment for Opioid Use Disorder, Retention, and Continuity of Care. APPENDIX 1: Literature Review

APPENDIX 1. LITERATURE REVIEW IBM Watson Health July 2020 DISCLAIMER: The opinions and views expressed in this report are those of the authors. They do not reflect the views of the Department of Health and Human Services, the contractor or any other funding organization. This report was completed and submitted on January 11, 2019.   TAB
Report
Models for Medication-Assisted Treatment for

Models for Medication-Assisted Treatment for Opioid Use Disorder, Retention, and Continuity of Care

MODELS FOR MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER, RETENTION, AND CONTINUITY OF CARE Peggy L. O'Brien, Kristin Schrader, Alex Waddell, and Norah Mulvaney-Day IBM Watson Health July 2020 Printer Friendly Version in PDF Format (150 PDF pages)
PDF report
Models for Medication-Assisted Treatment for

Models for Medication-Assisted Treatment for Opioid Use Disorder, Retention, and Continuity of Care

Treatment providers, policymakers, and others are seeking ways to reverse the tide of mortality and morbidity that has accompanied the opioid epidemic. There are evidence-based treatments for opioid use disorder (OUD), including medication-assisted treatment (MAT) using buprenorphine, methadone, and naltrexone. Research shows that retention in MAT
  • MATOUDModels.pdf
    export-csvPDF
PDF report
Public Listing Status of Data-Waivered Providers

Public Listing Status of Data-Waivered Providers: Data Brief

A large proportion of DATA-waivered providers choose not to be publicly listed on the SAMHSA website. Greater proportions of physician assistants and nurse practitioners, compared to physicians, opt to be listed on the SAMHSA website.
  • DWPlisting.pdf
    export-csvPDF
Basic report
Public Listing Status of Data-Waivered Providers

Public Listing Status of Data-Waivered Providers: Data Brief

Mir M. Ali, Robin Ghertner, Laurel Fuller, and Joel Dubenitz U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation Printer Friendly Version in PDF Format (3 PDF pages)
Basic report
State Policy Levers for Expanding Family-Centered

State Policy Levers for Expanding Family-Centered Medication-Assisted Treatment

Julie Seibert, PhD, Holly Stockdale, MA, Rose Feinberg, MA, Erin Dobbins, MA, Elysha Theis, BA, and Sarita L. Karon, PhD RTI International Printer Friendly Version in PDF Format (55 PDF pages)
PDF report
State Policy Levers for Expanding Family-Centered

State Policy Levers for Expanding Family-Centered Medication-Assisted Treatment

Many women facing opioid addiction are either pregnant or caring for children and face a number of social, structural and economic barrier in accessing treatment. In recent years, clinicians and policymakers have become increasingly interested in supporting substance use treatment approaches that provide comprehensive services to pregnant and pare
  • ExpandFCMAT.pdf
    export-csvPDF
Basic report
Expanding Access to Family-Centered Medication-

Expanding Access to Family-Centered Medication-Assisted Treatment Issue Brief

Printer Friendly Version in PDF Format (5 PDF pages) ABSTRACT This Issue Brief represents the finding of a white paper prepared by RTI under funding from ASPE. The analysis included a programs scan of policy initiatives in 21 states and individual interviews with academics, federal experts, state officials and individual providers.
PDF report
Expanding Access to Family-Centered Medication-

Expanding Access to Family-Centered Medication-Assisted Treatment Issue Brief

This Issue Brief represents the finding of a white paper prepared by RTI under funding from ASPE. The analysis included a programs scan of policy initiatives in 21 states and individual interviews with academics, federal experts, state officials and individual providers.
  • FCMATib.pdf
    export-csvPDF
PDF report
Data point: Prescription Pharmaceutical Price

Data point: Prescription Pharmaceutical Price Changes since the Release of the President’s Drug Pricing Blueprint

Using manufacturer-reported prescription pharmaceutical prices, we observe that the number of price increases has been reduced considerably since the release of the President’s Drug Pricing Blueprint, compared to the same time period in the year prior. Since the Blueprint’s release, there are 60% fewer brand name product price increases in 201
  • DPrxpricechanges100dayspostblueprint.pdf
    export-csvPDF